Pharmafile Logo

dual tasking

- PMLiVE

Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant

Data suggests vaccine is 64% effective at preventing infection caused by Delta variant after two doses

- PMLiVE

Imugene’s cancer vaccine shows promise in mid-stage stomach cancer trial

HER-Vaxx plus chemotherapy resulted in ORR of 50% compared to 29% for chemotherapy alone

- PMLiVE

MHRA outlines two-year delivery plan with ‘patient first’ focus

New delivery plan also outlines strategy for UK regulatory body following Brexit

- PMLiVE

AstraZeneca clears latest hurdle for Alexion acquisition after EU clearance

AZ first announced the proposed acquisition of Alexion in December 2020

FREE eBook: The Complete Guide to Virtualizing In-person Meetings

Download our latest eBook for free to learn about the innovative ways clients have used our synchronous and asynchronous virtual tools to engage participants and virtualize their meetings and events.

Impetus Digital

- PMLiVE

Bharat Biotech says its COVID-19 vaccine is 77.8% effective overall

US development partner Ocugen is already planning to submit a BLA for the vaccine to the FDA

- PMLiVE

Starting a career in medical communications – experiences from the Nucleus Academy (part 2)

Two more graduates of the Nucleus Academy training programme share their experiences of the Academy and their medical communications careers to date.

Nucleus Global

- PMLiVE

GSK supports CEO Emma Walmsley following Elliott’s demands for leadership overhaul

GSK’s board said that it ‘strongly believes’ Walmsley is the ‘right leader’ for the new biopharma business

- PMLiVE

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data

- PMLiVE

UK Supreme Court rules in favour of Servier in NHS patent lawsuit

The NHS alleged that the French pharma company tried to block sales of generics versions of its drug Coversyl

- PMLiVE

Q&A: Claire Gillis

PME interviews VMLY&Rx's CEO

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links